On Thursday, hearing aid manufacturer WS Audiology has released its financial report for the second quarter of 2022, meaning the company, which is privately owned by private equity fund EQT, is now half way through its financial year.
The company, which does not report bottom-line figures, performed well, growing its revenue by 20% (organically by 13%) to EUR 581m in the three-month period. WSA highlights that this brings the H1 revenue to EUR 1,163m, corresponding to growth of 17%.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
Analytical Senior Scientist 
Biostatistician 
Senior Manager, Clinical Trial Budget 
Senior Project Manager (GMP - Life Science) 
Account Manager 
Director for innovative pre-clinical testing unit 
SAP System Specialist (Product Supply) – Business Application Services 
Client Talent Acquisition Specialist 
Senior Chemical Safety Advisor 
Innovation Project Manager, Display Unit 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Nordic Medical Affairs Manager 
Scientific Writer 
System Sales Development Consultant - Investment Projects, Merck Millipore